Models attempting to quantify the relationship between drug development and financial return are missing a key...

Area of Science:

• Biopharmaceutical policy
• Health economics
• Drug development lifecycle

Background:

• The Inflation Reduction Act (IRA) introduced administrative drug price setting in the U.S.
• Existing economic models for policy assessment often overlook post-approval research and development.
• Post-approval studies are vital for expanding drug indications and verifying efficacy in new patient groups.

Purpose of the Study:

• To highlight the impact of the IRA's price-setting mechanisms on post-approval drug research investment.
• To emphasize the need for comprehensive economic models that include the entire drug development lifecycle.
• To inform policymakers about the potential unintended consequences of current policy assessments.

Main Methods:

• This commentary analyzes the economic implications of administrative drug price setting on pharmaceutical investment.
• It reviews existing policy impact models and identifies their limitations regarding post-market research.
• The analysis focuses on the financial incentives for developing secondary indications under price controls.

Main Results:

• The IRA's price controls, effective at the time of post-approval studies, diminish expected financial returns from secondary indications.
• This reduction in financial incentives may discourage investment in essential post-market research.
• Current policy models risk underestimating the negative impact on drug development due to the exclusion of post-approval research.

Conclusions:

• Models assessing biopharmaceutical policy must incorporate the effects on both new and post-approval drug development.
• Excluding post-approval research from economic evaluations is a significant gap, potentially harming health outcomes, especially for chronic diseases.
• Further research is needed to develop comprehensive models that support investment across the entire drug development lifecycle.